These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6412668)

  • 81. Mechanism of action of antiepileptic and antimyoclonic drugs.
    Pranzatelli MR; Nadi NS
    Adv Neurol; 1995; 67():329-60. PubMed ID: 8848979
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The man behind Lafora's bodies.
    Ortiz-Hidalgo C
    Am J Surg Pathol; 1986 May; 10(5):358-61. PubMed ID: 3085524
    [No Abstract]   [Full Text] [Related]  

  • 83. Lafora's disease in a dog.
    Davis KE; Finnie JW; Hooper PT
    Aust Vet J; 1990 May; 67(5):192-3. PubMed ID: 2165776
    [No Abstract]   [Full Text] [Related]  

  • 84. [The role of mitochondrial encephalopathies in progressive myoclonus epilepsy].
    Roger J; Bureau M; Dravet C; Genton P; Tassinari CA; Michelucci R
    Rev Neurol (Paris); 1991; 147(6-7):480-90. PubMed ID: 1962055
    [TBL] [Abstract][Full Text] [Related]  

  • 85. LAFORA'S DISEASE. DISTINCT CLINICO-PATHOLOGIC FORM OF UNVERRICHT'S SYNDROME.
    SCHWARZ GA; YANOFF M
    Arch Neurol; 1965 Feb; 12():172-88. PubMed ID: 14237775
    [No Abstract]   [Full Text] [Related]  

  • 86. Urinary glycosaminoglycans in patients with progressive myoclonus epilepsy.
    Federico A; D'Auria N
    J Neurol; 1979 Jan; 220(4):291-5. PubMed ID: 90138
    [TBL] [Abstract][Full Text] [Related]  

  • 87. GABA levels in cerebrospinal fluid of patients with epilepsy.
    Yamamoto M; Takahashi S; Otsuki S; Kugoh T; Hosokawa K; Ogawa N
    Folia Psychiatr Neurol Jpn; 1985; 39(4):515-9. PubMed ID: 3938765
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Deficient intestinal absorption of L-tryptophan in progressive myoclonus epilepsy without Lafora bodies.
    Koskiniemi ML
    J Neurol Sci; 1980 Jul; 47(1):1-6. PubMed ID: 6157783
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Transient effect of L-tryptophan in progressive myoclonus epilepsy without Lafora bodies: clinical and electrophysiological study.
    Koskiniemi M; Hyyppä M; Sainio K; Salmi T; Sarna S; Uotila L
    Epilepsia; 1980 Aug; 21(4):351-7. PubMed ID: 6772434
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Cerebrospinal fluid free choline in movement disorders of paediatric onset.
    Pranzatelli MR; Hanin I; Tate E; Kindel G; Bergin A; Brown CM; Habersang P; Habersang R; Mack KJ; Rosenbaum B; Selby KA; Vasconcellos M
    Eur J Paediatr Neurol; 1998; 2(1):33-9. PubMed ID: 10726844
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Mental deterioration in Lafora's disease.
    Cukiert A; Vilela MM; Scapolan HB; Lefèvre BH; Marques-Assis L
    Arq Neuropsiquiatr; 1990 Jun; 48(2):236-40. PubMed ID: 2124483
    [TBL] [Abstract][Full Text] [Related]  

  • 92. [Lafora's disease: diagnosis by muscle biopsy (case report)].
    Carvalho AA; Palou V; Rocha MS; Brucki SM; Argentoni M
    Arq Neuropsiquiatr; 2000 Dec; 58(4):1118-22. PubMed ID: 11105083
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Polyglucosan bodies in intramuscular motor nerves.
    Bernsen RA; Busard HL; Ter Laak HJ; Gabreëls FJ; Renier WO; Joosten EM; Theeuwes AG
    Acta Neuropathol; 1989; 77(6):629-33. PubMed ID: 2546356
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Lafora's disease in a dog.
    Mackenzie CD; Johnson RP
    Aust Vet J; 1976 Mar; 52(3):144. PubMed ID: 825089
    [No Abstract]   [Full Text] [Related]  

  • 95. Lafora's disease. An ultrastructural and histochemical study.
    Ramón y Cajal S; Blanes A; Martinez A; Sáenz E; Gutierrez M
    Acta Neuropathol; 1974; 30(3):189-96. PubMed ID: 4446965
    [No Abstract]   [Full Text] [Related]  

  • 96. Case Report: Distinctive EEG Patterns in SCARB-2 Related Progressive Myoclonus Epilepsy.
    Hotait M; Dirani M; El Halabi T; Beydoun A
    Front Genet; 2020; 11():581253. PubMed ID: 33343627
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Myoclonic encephalopathy due to bismuth salts: treatment with dimercaprol and analysis of CSF transmitters.
    Molina JA; Calandre L; Bermejo F
    Acta Neurol Scand; 1989 Mar; 79(3):200-3. PubMed ID: 2566254
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Inosine as a Tool to Understand and Treat Central Nervous System Disorders: A Neglected Actor?
    Nascimento FP; Macedo-Júnior SJ; Lapa-Costa FR; Cezar-Dos-Santos F; Santos ARS
    Front Neurosci; 2021; 15():703783. PubMed ID: 34504414
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Progressive Myoclonic Epilepsies.
    Uthman BM; Reichl A
    Curr Treat Options Neurol; 2002 Jan; 4(1):3-17. PubMed ID: 11734100
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Increase in adenosine metabolites in human cerebrospinal fluid after status epilepticus.
    Chin JH; Wiesner JB; Fujitaki J
    J Neurol Neurosurg Psychiatry; 1995 Apr; 58(4):513-4. PubMed ID: 7738576
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.